Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HCM HUTCHMED	$15.25 -0.1%	$14.76	$12.84 ▼ $21.92	$2.66B	0.77	106,390 shs	68,602 shs
MLTX MoonLake Immunotherapeutics	$39.86 +0.1%	$42.17	$36.52 ▼ $58.26	$2.55B	1.31	339,147 shs	431,032 shs
NAMS NewAmsterdam Pharma	$21.76 -2.9%	$21.66	$15.19 ▼ $27.29	$2.39B	-0.04	532,561 shs	690,361 shs
NUVB Nuvation Bio	$1.82 -2.9%	$2.19	$1.71 ▼ $3.97	$614.70M	1.47	1.94 million shs	1.43 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HCM HUTCHMED	0.00%	+1.73%	-7.35%	+6.20%	-9.23%
MLTX MoonLake Immunotherapeutics	0.00%	-0.65%	-4.55%	-24.82%	-20.65%
NAMS NewAmsterdam Pharma	0.00%	-8.84%	+3.62%	-15.00%	-7.99%
NUVB Nuvation Bio	0.00%	-4.22%	-7.16%	-30.73%	-50.14%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HCM HUTCHMED	1.8626 of 5 stars	2.0	3.0	3.6	0.0	1.9
MLTX MoonLake Immunotherapeutics	2.2144 of 5 stars	3.5	1.0	3.7	2.5	0.0
NAMS NewAmsterdam Pharma	2.4565 of 5 stars	3.5	1.0	2.8	4.2	0.0
NUVB Nuvation Bio	1.9895 of 5 stars	3.6	0.0	3.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HCM HUTCHMED	2.00	Hold	$19.00	24.59% Upside
MLTX MoonLake Immunotherapeutics	3.00	Buy	$80.50	101.96% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$43.33	99.14% Upside
NUVB Nuvation Bio	3.25	Buy	$8.75	382.09% Upside

Current Analyst Ratings Breakdown

Latest NUVB, NAMS, HCM, and MLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/27/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00
3/18/2025	MLTX MoonLake Immunotherapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$67.00
3/12/2025	NUVB Nuvation Bio	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
3/11/2025	NUVB Nuvation Bio	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/10/2025	NUVB Nuvation Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
3/3/2025	NAMS NewAmsterdam Pharma	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$41.00
3/3/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00
2/27/2025	MLTX MoonLake Immunotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$82.00 ➝ $73.00
2/27/2025	MLTX MoonLake Immunotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$62.00 ➝ $66.00
2/27/2025	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
2/27/2025	NAMS NewAmsterdam Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$47.00 ➝ $52.00

(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HCM HUTCHMED	$630.20M	4.22	$0.62 per share	24.51	$4.27 per share	3.57
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$8.15 per share	N/A
NAMS NewAmsterdam Pharma	$45.56M	52.45	N/A	N/A	$3.50 per share	6.22
NUVB Nuvation Bio	$7.87M	78.08	N/A	N/A	$2.76 per share	0.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HCM HUTCHMED	$100.78M	N/A	0.00	10.45	N/A	N/A	N/A	N/A	5/9/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$36.01M	-$1.89	N/A	N/A	N/A	N/A	-15.54%	-15.09%	5/6/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$176.94M	-$2.60	N/A	N/A	N/A	N/A	N/A	N/A	5/14/2025 (Estimated)
NUVB Nuvation Bio	-$75.80M	-$2.26	N/A	N/A	N/A	N/A	-21.89%	-17.86%	5/13/2025 (Estimated)

Latest NUVB, NAMS, HCM, and MLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/26/2025	Q4 2024	MLTX MoonLake Immunotherapeutics	-$0.63	-$0.72	-$0.09	-$0.72	N/A	N/A
2/26/2025	Q4 2024	NAMS NewAmsterdam Pharma	-$0.48	-$0.95	-$0.47	-$0.95	$3.30 million	$12.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HCM HUTCHMED	0.07	2.81	2.68
MLTX MoonLake Immunotherapeutics	N/A	25.51	25.51
NAMS NewAmsterdam Pharma	N/A	10.61	10.61
NUVB Nuvation Bio	N/A	9.57	9.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HCM HUTCHMED	8.82%
MLTX MoonLake Immunotherapeutics	93.85%
NAMS NewAmsterdam Pharma	89.89%
NUVB Nuvation Bio	61.67%

Insider Ownership

Company	Insider Ownership
HCM HUTCHMED	3.60%
MLTX MoonLake Immunotherapeutics	12.02%
NAMS NewAmsterdam Pharma	19.50%
NUVB Nuvation Bio	5.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HCM HUTCHMED	1,988	174.32 million	168.04 million	Not Optionable
MLTX MoonLake Immunotherapeutics	2	64.01 million	56.22 million	Optionable
NAMS NewAmsterdam Pharma	4	109.82 million	74.37 million	Optionable
NUVB Nuvation Bio	60	338.68 million	319.50 million	Optionable

NUVB, NAMS, HCM, and MLTX Headlines

Recent News About These Companies

Nuvation Bio (NYSE:NUVB) Receives "Outperform" Rating from Wedbush

March 28 at 8:23 PM | marketbeat.com

Nuvation Bio Inc. (NYSE:NUVB) Stock Position Boosted by Charles Schwab Investment Management Inc.

March 26, 2025 | marketbeat.com

Insider Stock Buying Reaches US$720.1k On Nuvation Bio

March 25, 2025 | uk.finance.yahoo.com

Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025

March 25, 2025 | businesswire.com

Stock Traders Purchase Large Volume of Nuvation Bio Put Options (NYSE:NUVB)

March 22, 2025 | americanbankingnews.com

Stock Traders Buy High Volume of Nuvation Bio Put Options (NYSE:NUVB)

March 21, 2025 | marketbeat.com

Is Nuvation Bio Inc. (NYSE:NUVB) the Most Oversold Penny Stocks to Buy According to Analysts?

March 17, 2025 | msn.com

Nuvation Bio (NYSE:NUVB) Shares Down 2.5% - Time to Sell?

March 15, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Upgraded to "Strong-Buy" at Jones Trading

March 15, 2025 | marketbeat.com

Nuvation Bio Inc. (NYSE:NUVB) Receives Consensus Recommendation of "Buy" from Analysts

March 13, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Coverage Initiated by Analysts at Jones Trading

March 13, 2025 | marketbeat.com

Jones Trading Initiates Coverage of Nuvation Bio (NUVB) with Buy Recommendation

March 12, 2025 | msn.com

Q1 EPS Estimates for Nuvation Bio Lowered by HC Wainwright

March 12, 2025 | marketbeat.com

Nuvation Bio initiated with a Buy at JonesResearch

March 11, 2025 | markets.businessinsider.com

Nuvation Bio price target lowered to $10 from $11 at H.C. Wainwright

March 10, 2025 | markets.businessinsider.com

Nuvation Bio (NYSE:NUVB) Shares Gap Down After Analyst Downgrade

March 10, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Given New $10.00 Price Target at HC Wainwright

March 10, 2025 | marketbeat.com

Q1 Earnings Estimate for Nuvation Bio Issued By Wedbush

March 10, 2025 | marketbeat.com

Nuvation Bio Inc. (NUVB): Among the Best NYSE Penny Stocks to Buy According to Analysts

March 9, 2025 | insidermonkey.com

Nuvation Bio (NYSE:NUVB) Stock Price Up 8% - Still a Buy?

March 8, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Releases Earnings Results, Misses Estimates By $0.01 EPS

March 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB, NAMS, HCM, and MLTX Company Descriptions

HUTCHMED NASDAQ:HCM

$15.25 -0.01 (-0.07%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$15.25 0.00 (0.00%)

As of 03/28/2025 04:05 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

MoonLake Immunotherapeutics NASDAQ:MLTX

$39.86 +0.02 (+0.05%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$39.90 +0.04 (+0.09%)

As of 03/28/2025 04:02 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

NewAmsterdam Pharma NASDAQ:NAMS

$21.76 -0.65 (-2.90%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$21.76 +0.00 (+0.02%)

As of 03/28/2025 04:09 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Nuvation Bio NYSE:NUVB

$1.82 -0.06 (-2.94%)

Closing price 03/28/2025 03:59 PM Eastern

Extended Trading

$1.82 0.00 (0.00%)

As of 03/28/2025 06:53 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time